Literature DB >> 24234234

Cysteine cathepsins in neurological disorders.

Anja Pišlar1, Janko Kos.   

Abstract

Increased proteolytic activity is a hallmark of several pathological processes, including neurodegeneration. Increased expression and activity of cathepsins, lysosomal cysteine proteases, during degeneration of the central nervous system is frequently reported. Recent studies reveal that a disturbed balance of their enzymatic activities is the first insult in brain aging and age-related diseases. Leakage of cathepsins from lysosomes, due to their membrane permeability, and activation of pro-apoptotic factors additionally contribute to neurodegeneration. Furthermore, in inflammation-induced neurodegeneration the cathepsins expressed in activated microglia play a pivotal role in neuronal death. The proteolytic activity of cysteine cathepsins is controlled by endogenous protein inhibitors-the cystatins-which evidently fail to perform their function in neurodegenerative processes. Exogenous synthetic inhibitors, which may augment their inhibitory potential, are considered as possible therapeutic tools for the treatment of neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24234234     DOI: 10.1007/s12035-013-8576-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  167 in total

1.  Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro.

Authors:  Ales Premzl; Valentina Zavasnik-Bergant; Vito Turk; Janko Kos
Journal:  Exp Cell Res       Date:  2003-02-15       Impact factor: 3.905

2.  Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus.

Authors:  E Bednarski; C E Ribak; G Lynch
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

3.  Instability of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type.

Authors:  L Wei; Y Berman; E M Castaño; M Cadene; R C Beavis; L Devi; E Levy
Journal:  J Biol Chem       Date:  1998-05-08       Impact factor: 5.157

4.  The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.

Authors:  Gregory Hook; Vivian Hook; Mark Kindy
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro.

Authors:  H Beck; G Schwarz; C J Schröter; M Deeg; D Baier; S Stevanovic; E Weber; C Driessen; H Kalbacher
Journal:  Eur J Immunol       Date:  2001-12       Impact factor: 5.532

6.  Systemic administration of lipopolysaccharide induces molecular and morphological alterations in the hippocampus.

Authors:  Grzegorz A Czapski; Barbara Gajkowska; Joanna B Strosznajder
Journal:  Brain Res       Date:  2010-08-07       Impact factor: 3.252

7.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter.

Authors:  Sukkid Yasothornsrikul; Doron Greenbaum; Katalin F Medzihradszky; Thomas Toneff; Richard Bundey; Ruthellen Miller; Birgit Schilling; Ivonne Petermann; Jessica Dehnert; Anna Logvinova; Paul Goldsmith; John M Neveu; William S Lane; Bradford Gibson; Thomas Reinheckel; Christoph Peters; Matthew Bogyo; Vivian Hook
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

8.  Differential distribution of messenger RNAs for cathepsins B, L and S in adult rat brain: an in situ hybridization study.

Authors:  S Petanceska; S Burke; S J Watson; L Devi
Journal:  Neuroscience       Date:  1994-04       Impact factor: 3.590

9.  Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation.

Authors:  Kai Fan; Xuefei Wu; Bin Fan; Ning Li; Yongzhong Lin; Yiwen Yao; Jianmei Ma
Journal:  J Neuroinflammation       Date:  2012-05-20       Impact factor: 8.322

10.  Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons.

Authors:  Qiuli Liang; Xiaosen Ouyang; Lonnie Schneider; Jianhua Zhang
Journal:  Mol Neurodegener       Date:  2011-06-01       Impact factor: 14.195

View more
  28 in total

1.  Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration.

Authors:  Chan Chung; Prasanth Puthanveetil; Daniel S Ory; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2016-01-28       Impact factor: 6.150

2.  Cathepsins in heart disease-chewing on the heartache?

Authors:  Jordan Blondelle; Stephan Lange; Barry H Greenberg; Randy T Cowling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

3.  Plasma signature of neurological disease in the monogenetic disorder Niemann-Pick Type C.

Authors:  Md Suhail Alam; Michelle Getz; Sue Yi; Jeffrey Kurkewich; Innocent Safeukui; Kasturi Haldar
Journal:  J Biol Chem       Date:  2014-01-31       Impact factor: 5.157

4.  S-Nitrosylation of cathepsin B affects autophagic flux and accumulation of protein aggregates in neurodegenerative disorders.

Authors:  Ki-Ryeong Kim; Eun-Jung Cho; Jae-Won Eom; Sang-Seok Oh; Tomohiro Nakamura; Chang-Ki Oh; Stuart A Lipton; Yang-Hee Kim
Journal:  Cell Death Differ       Date:  2022-04-24       Impact factor: 12.067

Review 5.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

6.  Lysosomal Cathepsin Protease Gene Expression Profiles in the Human Brain During Normal Development.

Authors:  Amy Hsu; Sonia Podvin; Vivian Hook
Journal:  J Mol Neurosci       Date:  2018-07-14       Impact factor: 3.444

Review 7.  Cathepsin D-Managing the Delicate Balance.

Authors:  Olja Mijanovic; Anastasiia I Petushkova; Ana Brankovic; Boris Turk; Anna B Solovieva; Angelina I Nikitkina; Sergey Bolevich; Peter S Timashev; Alessandro Parodi; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-06-05       Impact factor: 6.321

8.  Genome-Wide Screen and Validation of Microglia Pro-Inflammatory Mediators in Stroke.

Authors:  Jianhua Wu; Zhuoze Wu; Aodi He; Tongmei Zhang; Ping Zhang; Jing Jin; Sisi Li; Gaigai Li; Xinyan Li; Shiqi Liang; Lei Pei; Rong Liu; Qing Tian; Ximiao He; Youming Lu; Zhouping Tang; Hao Li
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

9.  Perturbations of the Proteome and of Secreted Metabolites in Primary Astrocytes from the hSOD1(G93A) ALS Mouse Model.

Authors:  Roberto Stella; Raphael Severino Bonadio; Stefano Cagnin; Maria Lina Massimino; Alessandro Bertoli; Caterina Peggion
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 10.  MHC Class II Auto-Antigen Presentation is Unconventional.

Authors:  Scheherazade Sadegh-Nasseri; AeRyon Kim
Journal:  Front Immunol       Date:  2015-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.